BRPI0508703A - processo para a sìntese de um antagonista de cxcr4 - Google Patents
processo para a sìntese de um antagonista de cxcr4Info
- Publication number
- BRPI0508703A BRPI0508703A BRPI0508703-1A BRPI0508703A BRPI0508703A BR PI0508703 A BRPI0508703 A BR PI0508703A BR PI0508703 A BRPI0508703 A BR PI0508703A BR PI0508703 A BRPI0508703 A BR PI0508703A
- Authority
- BR
- Brazil
- Prior art keywords
- amine
- protected
- synthesis
- compound
- imine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55358904P | 2004-03-15 | 2004-03-15 | |
US60/553,589 | 2004-03-15 | ||
PCT/US2005/008268 WO2005090308A1 (en) | 2004-03-15 | 2005-03-11 | Process for the synthesis of a cxcr4 antagonist |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0508703A true BRPI0508703A (pt) | 2007-08-07 |
BRPI0508703B1 BRPI0508703B1 (pt) | 2020-11-24 |
BRPI0508703B8 BRPI0508703B8 (pt) | 2021-05-25 |
Family
ID=34993619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508703A BRPI0508703B8 (pt) | 2004-03-15 | 2005-03-11 | processo para a síntese de um antagonista de cxcr4 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7332605B2 (pt) |
EP (1) | EP1730113B1 (pt) |
JP (1) | JP4870660B2 (pt) |
KR (1) | KR20060131899A (pt) |
CN (1) | CN1930127B (pt) |
AU (1) | AU2005224079A1 (pt) |
BR (1) | BRPI0508703B8 (pt) |
CA (1) | CA2558389C (pt) |
ES (1) | ES2614508T3 (pt) |
IL (1) | IL177511A (pt) |
NO (1) | NO20064200L (pt) |
RU (1) | RU2006136381A (pt) |
WO (1) | WO2005090308A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
AR050522A1 (es) * | 2004-08-16 | 2006-11-01 | Smithkline Beecham Corp | Derivados de bencimidazol como moduladores de la actividad de los receptores de quimioquina; composiciones farmaceuticas que los contienen; metodos para su preparacion y su uso en la fabricacion de medicamentos para el tratamiento contra infecciones por hiv |
TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
WO2007087549A2 (en) * | 2006-01-25 | 2007-08-02 | Smithkline Beecham Corporation | Chemical compounds |
JP2009524689A (ja) * | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
MX2009001272A (es) * | 2006-08-02 | 2009-02-11 | Genzyme Corp | Terapia de combinacion. |
EP2209766A1 (en) * | 2007-04-26 | 2010-07-28 | Dr. Reddy's Laboratories (EU) Limited | Novel aldehyde composition |
FR2934859B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
MA34591B1 (fr) | 2010-10-06 | 2013-10-02 | Glaxosmithkline Llc | Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase |
US10953003B2 (en) | 2015-12-14 | 2021-03-23 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
ES2935834T3 (es) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Métodos para tratar enfermedad de inmunodeficiencia |
GB201604213D0 (en) * | 2016-03-11 | 2016-04-27 | Proximagen Ltd | Drug combination and its use in therapy |
WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CA3027498A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
JP2023524522A (ja) | 2020-05-01 | 2023-06-12 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. | 抗covid-19剤としてのeタンパク質チャネル遮断薬およびorf3阻害剤 |
WO2022113069A1 (en) | 2020-11-24 | 2022-06-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | E protein channel blockers and orf3 inhibitors as anti-covid-19 agents |
AU2022360035A1 (en) * | 2021-10-07 | 2024-04-18 | X4 Pharmaceuticals, Inc. | Synthesis of mavorixafor and intermediates thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9400411D0 (en) * | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
PT988038E (pt) * | 1997-06-02 | 2002-12-31 | Janssen Pharmaceutica Nv | Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos |
BR0010655A (pt) | 1999-03-24 | 2002-02-13 | Anormed Inc | Compostos heterocìclicos para ligação ao receptor de quimiocina |
US6864265B2 (en) * | 2000-09-15 | 2005-03-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
ES2269465T3 (es) * | 2000-09-15 | 2007-04-01 | Anormed Inc | Compuestos heterociclicos de union a los receptores de la quimioquina. |
CZ10903U1 (en) * | 2001-01-11 | 2001-02-19 | Oldrich Ing Cihak | Bladed water wheel |
US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
IL161784A0 (en) * | 2001-12-21 | 2005-11-20 | Anormed Inc | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
-
2005
- 2005-03-11 AU AU2005224079A patent/AU2005224079A1/en not_active Abandoned
- 2005-03-11 RU RU2006136381/04A patent/RU2006136381A/ru not_active Application Discontinuation
- 2005-03-11 CN CN2005800069769A patent/CN1930127B/zh active Active
- 2005-03-11 BR BRPI0508703A patent/BRPI0508703B8/pt active IP Right Grant
- 2005-03-11 ES ES05725450.0T patent/ES2614508T3/es active Active
- 2005-03-11 WO PCT/US2005/008268 patent/WO2005090308A1/en active Application Filing
- 2005-03-11 KR KR1020067019097A patent/KR20060131899A/ko not_active Application Discontinuation
- 2005-03-11 CA CA2558389A patent/CA2558389C/en active Active
- 2005-03-11 JP JP2007503981A patent/JP4870660B2/ja active Active
- 2005-03-11 US US11/077,896 patent/US7332605B2/en active Active
- 2005-03-11 EP EP05725450.0A patent/EP1730113B1/en active Active
-
2006
- 2006-08-16 IL IL177511A patent/IL177511A/en active IP Right Grant
- 2006-09-15 NO NO20064200A patent/NO20064200L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2558389A1 (en) | 2005-09-29 |
JP2007529526A (ja) | 2007-10-25 |
EP1730113A4 (en) | 2009-12-02 |
EP1730113A1 (en) | 2006-12-13 |
IL177511A0 (en) | 2006-12-10 |
US20050209277A1 (en) | 2005-09-22 |
US7332605B2 (en) | 2008-02-19 |
KR20060131899A (ko) | 2006-12-20 |
NO20064200L (no) | 2006-09-15 |
RU2006136381A (ru) | 2008-04-27 |
BRPI0508703B1 (pt) | 2020-11-24 |
CA2558389C (en) | 2013-10-08 |
CN1930127A (zh) | 2007-03-14 |
IL177511A (en) | 2010-12-30 |
BRPI0508703B8 (pt) | 2021-05-25 |
EP1730113B1 (en) | 2016-12-28 |
AU2005224079A1 (en) | 2005-09-29 |
CN1930127B (zh) | 2012-11-21 |
JP4870660B2 (ja) | 2012-02-08 |
WO2005090308A1 (en) | 2005-09-29 |
ES2614508T3 (es) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508703A (pt) | processo para a sìntese de um antagonista de cxcr4 | |
BRPI0500585A (pt) | Processo para a sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável | |
BRPI0500480A (pt) | processo para a sìntese de (1s)-4,5-dimetóxi- 1-(metilaminometil)-benzociclobutano e sais de adição deste, e aplicação na sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável | |
BRPI0519262A2 (pt) | derivados de pirazol fundidos e mÉtodos de tratamento de distérbios metabàlicos-relacionados destes | |
BR0313545B1 (pt) | processos para a preparação de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila | |
BR0306150A (pt) | Composto, uso de um composto, e, composição farmacêutica | |
BRPI0619255B8 (pt) | composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer | |
BR0213792A (pt) | Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3) | |
MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
ATE402945T1 (de) | Neuer steroidagonist für fxr | |
BRPI0507617A (pt) | antagonistas de receptor de quimiocina | |
BRPI0606455A (pt) | compostos farmacêuticos | |
BR9803179A (pt) | Antagonistas receptores de ccr-3. | |
ATE414703T1 (de) | Isoxazolderivate als inverse gaba a alpha5 agonisten | |
BRPI0614524B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto | |
ATE449082T1 (de) | (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor | |
DE60235396D1 (de) | 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung | |
BRPI0500590B8 (pt) | processo para a síntese de compostos de 1,3,4,5-tetraidro-2h-3-benzazepin-2-ona, e aplicação na síntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável | |
BRPI0900983A2 (pt) | compostos de diometina, processo para sua preparação e composições farmacêuticas contendo os mesmos | |
BRPI0804091B8 (pt) | compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm | |
BRPI0519208A2 (pt) | derivados de pirrolinÍdio como receptores muscarÍnicos m3 | |
BRPI0509384A (pt) | processo de hidrogenação assimétrica para a preparação de um composto ou um sal do mesmo, e, composto ou um sal do mesmo | |
BRPI0409258B8 (pt) | processo para resolução de compostos racêmicos | |
BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
BRPI0602132A (pt) | compostos de indanil-piperazina, processo para sua preparação e composições farmacêuticas contendo os mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |